The Trentonian

Novartis receives FDA approval of Xolair(R) (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

EAST HANOVER, N.J., April 12, 2021 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (R) ...
Business Wire

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Nasdaq

FDA Accepts Application for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indications

– If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs – – Filing acceptance is based on the well-established efficacy and ...
Nasdaq

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...